全球转甲状腺素类淀粉沉积症变性治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计到 2025 年，转甲状腺素类淀粉沉积症治疗市场规模将达到 732 万美元，到 2034 年将达到 1,560 万美元，2026 年至 2034 年的复合年增长率为 8.77%。

随着人们对转类淀粉沉积症样变性这种罕见疾病的认识和诊断水平的提高，预计该疾病的治疗市场将迎来显着增长。转甲状腺素类淀粉沉积症（ATTR）是一种进行性疾病，其特征是淀粉样蛋白在各种组织中积聚，最终导致器官功能障碍。 ATTR 的盛行率不断上升，尤其是在高龄化社会中，这推动了对有效治疗方法的需求。随着医疗机构致力于改善患者的治疗效果和生活质量，预计 ATTR 治疗市场将持续扩张。

技术创新在塑造转甲状腺素类淀粉沉积症变性治疗市场的未来方面发挥关键作用。药物研发领域的创新，包括小分子疗法和基因静默技术，正在提高旨在抑制淀粉样蛋白沉积和控制症状的治疗效果。此外，诊断工具的进步使得疾病的早期检测和更精准的后续观察成为可能，为及时介入奠定了基础。随着製药公司持续加大研发投入，预计转甲状腺素类淀粉沉积症样变性治疗市场将迎来新型治疗方法和更完善的患者管理策略的广泛应用。

此外，对以患者为中心的护理和支持的日益重视也推动了转甲状腺素类淀粉沉积症变性治疗市场的成长。随着患者及其家属对疾病和可用治疗方案的了解不断加深，对能够兼顾医疗和心理需求的综合护理计划的需求也日益增长。这一趋势促使医疗服务提供者、患者权益组织和研究人员携手合作，共同开发教育资源和支持网络，帮助患者在整个治疗过程中增强自主能力。随着市场的不断发展，技术整合、患者参与和全面护理方法将是成功的关键。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球转甲状腺素类淀粉沉积症变性治疗市场（依药物类型划分）

• 市场分析、洞察与预测
• 塔法米迪斯
• 派蒂西兰
• 伊诺特森
• 其他的

5. 全球转甲状腺素类淀粉沉积症变性治疗市场（依疾病类型划分）

• 市场分析、洞察与预测
• 遗传性转甲状腺素蛋白类淀粉沉积症
• 野生型转甲状腺素蛋白类淀粉沉积症

6. 全球转甲状腺素类淀粉沉积症治疗市场（依最终用户划分）

• 市场分析、洞察与预测
• 医院
• 居家照护
• 专科诊所
• 其他的

7. 全球转甲状腺素类淀粉沉积症治疗药物市场（依分销管道划分）

• 市场分析、洞察与预测
• 医院药房
• 网路药房
• 零售药房

8. 全球转甲状腺素类淀粉沉积症变性治疗市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Pfizer Inc
  • AstraZeneca
  • Prothena Corporation Plc
  • Ionis Pharmaceuticals
  • Bellus Health Inc
  • Alnylam Pharmaceuticals Inc
  • Eidos Therapeutics Inc
  • Som Biotech
  • Abbvie Inc
  • Bausch Health Companies Inc
  • Bristol Myers Squibb Company GSK Plc
  • Merck KGaA
  • Sanofi

The Transthyretin Amyloidosis Treatment Market size is expected to reach USD 15.60 Million in 2034 from USD 7.32 Million (2025) growing at a CAGR of 8.77% during 2026-2034.

The Transthyretin Amyloidosis Treatment Market is poised for significant growth as awareness and diagnosis of this rare disease increase. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the accumulation of amyloid proteins in various tissues, leading to organ dysfunction. The rising prevalence of ATTR, particularly among aging populations, is driving the demand for effective treatment options. As healthcare providers seek to improve patient outcomes and quality of life, the market for ATTR treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the transthyretin amyloidosis treatment market. Innovations in drug development, including small molecule therapies and gene silencing techniques, are enhancing the efficacy of treatments aimed at reducing amyloid deposits and managing symptoms. Additionally, advancements in diagnostic tools are enabling earlier detection and more accurate monitoring of the disease, which is critical for timely intervention. As pharmaceutical companies continue to invest in research and development, the transthyretin amyloidosis treatment market is likely to see increased adoption of novel therapies and improved patient management strategies.

Moreover, the growing emphasis on patient-centered care and support is influencing the transthyretin amyloidosis treatment market's growth trajectory. As patients and their families become more informed about the disease and available treatment options, there is a rising demand for comprehensive care plans that address both medical and emotional needs. This trend is driving collaboration between healthcare providers, patient advocacy groups, and researchers to develop educational resources and support networks that empower patients in their treatment journey. As the market continues to evolve, the integration of technology, patient engagement, and holistic care approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Tafamidis
• Patisiran
• Inotersen
• Others

By Diseases Type

• Hereditary Transthyretin Amyloidosis
• Wild Transthyretin Amyloidosis

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

COMPANIES PROFILED

• Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, Bellus Health Inc, Alnylam Pharmaceuticals Inc, Eidos Therapeutics Inc, Som Biotech, Abbvie Inc, Bausch Health Companies Inc, Bristol Myers Squibb Company GSK Plc, Merck KGaA, Sanofi

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN and Units)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Tafamidis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.3. Patisiran Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.4. Inotersen Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 5. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISEASES TYPE 2022-2034 (USD MN and Units)

• 5.1. Market Analysis, Insights and Forecast Diseases Type
• 5.2. Hereditary Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 5.3. Wild Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 6. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN and Units)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 7. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Units)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 7.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 7.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 8. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN and Units)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.2.1 By Drug Type
  • 8.2.2 By Diseases Type
  • 8.2.3 By End User
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.3.1 By Drug Type
  • 8.3.2 By Diseases Type
  • 8.3.3 By End User
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.4.1 By Drug Type
  • 8.4.2 By Diseases Type
  • 8.4.3 By End User
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.5.1 By Drug Type
  • 8.5.2 By Diseases Type
  • 8.5.3 By End User
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.6.1 By Drug Type
  • 8.6.2 By Diseases Type
  • 8.6.3 By End User
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 AstraZeneca
  • 10.2.3 Prothena Corporation Plc
  • 10.2.4 Ionis Pharmaceuticals
  • 10.2.5 Bellus Health Inc
  • 10.2.6 Alnylam Pharmaceuticals Inc
  • 10.2.7 Eidos Therapeutics Inc
  • 10.2.8 Som Biotech
  • 10.2.9 Abbvie Inc
  • 10.2.10 Bausch Health Companies Inc
  • 10.2.11 Bristol Myers Squibb Company GSK Plc
  • 10.2.12 Merck KGaA
  • 10.2.13 Sanofi